Dechert Advises Virbac on Acquisition of Assets From Elanco Animal Health Inc
March 22, 2021
Dechert advised Virbac, a French pharmaceutical group dedicated to animal health, in connection with its acquisition of certain assets and research programs from Elanco Animal Health Inc, a U.S. animal health pharmaceutical company.
As a result of prior commitments made by Elanco to the European Commission in connection with the acquisition of Bayer Animal Health, Virbac obtained the rights to acquire certain projects related to the development of innovative parasiticide products from Elanco in February 2021. In addition, Virbac has also obtained the global rights to two companion animal products, Itrafungol and Clomicalm.
This transaction required close cooperation between Dechert’s M&A and antitrust teams to ensure that the acquisition agreements being negotiated complied with the terms of the European Commission Decision, while simultaneously running an additional negotiation for the acquisition of other products not subject to the European Commission Decision.
Dechert advised Virbac on the following aspects:
- Antitrust: Mélanie Thill-Tayara and Laurence Bary, partners
- M&A: Ermine Bolot, partner, Pierre-Henri Brieau (Paris) and John Alessi (Boston), associates
About Dechert
Dechert is a leading global law firm with 25 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
